| Texto completo | |
| Autor(es): |
Tofoli, Giovana Radomille
[1]
;
Cereda, Cintia M. S.
[2]
;
Araujo, Daniele Ribeiro
[3]
;
Franz-Montan, Michelle
[2]
;
Groppo, Francisco Carlos
[4]
;
Quaglio, Daiane
[5]
;
Pedrazzoli Junior, Jose
[1]
;
Calafatti, Silvana Aparecida
[1]
;
Proenca Barros, Fabio Alessandro
[5]
;
de Paula, Eneida
[2]
Número total de Autores: 10
|
| Afiliação do(s) autor(es): | [1] Univ Sao Francisco, BR-12916900 Braganca Paulista, SP - Brazil
[2] Univ Estadual Campinas, Inst Biol, Dept Biochem, Campinas, SP - Brazil
[3] Fed Univ ABC, Santo Andre, SP - Brazil
[4] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Sao Paulo - Brazil
[5] CORE, Lab Clin Anal, Braganca Paulista, SP - Brazil
Número total de Afiliações: 5
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Journal of Pharmacy and Pharmacology; v. 64, n. 3, p. 397-403, MAR 2012. |
| Citações Web of Science: | 7 |
| Resumo | |
Objectives The pharmacokinetics of commercial and liposome-encapsulated mepivacaine (MVC) injected intra-orally in healthy volunteers was studied. Methods In this double blind, randomized cross-over study, 15 volunteers received, at four different sessions, 1.8 ml of the following formulations: 2% MVC with 1 : 100 000 epinephrine (MVC2%EPI), 3% MVC (MVC3%), 2% and 3% liposomeen-capsulated MVC (MVC2%LUV and MVC3%LUV). Blood samples were collected pre dose (0 min) and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 min after injections. Liquid chromatography-tandem mass spectrometry was used to quantify plasma MVC concentrations. Results Pharmacokinetic analysis showed that the maximum plasma concentration (Cmax) and the areas under the curves (AUC(0-360) and AUC(0-infinity)) after MVC2%LUV and MVC2%EPI injections were smaller (P < 0.05) than the equivalent figures for MVC3% and MVC3%LUV. The time to maximum plasma concentration (Tmax) and the half-life of elimination (t1/2beta) obtained after the treatment with MVC2%LUV, MVC2%EPI, MVC3% and MVC3%LUV presented no statistically significant differences (P > 0.05). Cmax, AUC(0-360) and AUC(0-infinity) after injection of the 2% formulations (MVC2%LUV and MVC2%EPI) did not exhibit statistically significant differences (P > 0.05). The pharmacokinetics of MVC2%LUV were comparable to the pharmacokinetics of MVC2%EPI. Conclusion The liposomal formulation of 2% MVC exhibits similar systemic absorption to the local anesthetic with vasoconstrictor. (AU) | |
| Processo FAPESP: | 06/00121-9 - Novas formulações de anestésicos locais de liberação controlada: do desenvolvimento ao teste clínico odontológico |
| Beneficiário: | Eneida de Paula |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |